Skip to main content

Sleep Apnea

7
Pipeline Programs
17
Companies
28
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

15 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
1
MontelukastPhase 2
SuvorexantPhase 1
MSD
MSDIreland - Ballydine
2 programs
1
1
MontelukastPhase 21 trial
SuvorexantPhase 11 trial
Active Trials
NCT01300455Completed26Est. Aug 2011
NCT00599534Withdrawn0Est. Dec 2009
Shionogi
ShionogiJapan - Osaka
1 program
1
SivopixantPhase 2
Apnimed
ApnimedMA - Cambridge
1 program
1
SivopixantPhase 21 trial
Active Trials
NCT06776432Recruiting60Est. Dec 2025
VIVUS
VIVUSCA - Campbell
1 program
1
VI-0521Phase 1/21 trial
Active Trials
NCT00745251Completed45Est. Dec 2009
ResMed
ResMedSAN DIEGO, CA
8 programs
14 days of placebo therapyN/A1 trial
Adaptive Servo-VentilationN/A1 trial
AirSense 10 AutoSet for HerN/A1 trial
Nexus Flow GeneratorN/A1 trial
RehaSleep Register - Prevalence of Sleep Apnea in Cardiac RehabilitationN/A1 trial
+3 more programs
Active Trials
NCT01196117Completed18Est. Dec 2011
NCT00263757Completed25Est. May 2012
NCT03043703Withdrawn0Est. Jun 2020
+4 more trials
Invicta Medical
Invicta MedicalCA - Santa Clara
5 programs
Hypoglossal nerve and/or Ansa Cervicalis stimulationN/A1 trial
Hypoglossal nerve stimulationN/A1 trial
Hypoglossal nerve stimulationN/A1 trial
Target StimulationN/A1 trial
Target stimulationN/A1 trial
Active Trials
NCT06415981Active Not Recruiting7Est. Jul 2024
NCT06283030Completed14Est. Sep 2023
NCT06283017Unknown14Est. Mar 2024
+2 more trials
Philips
PhilipsNetherlands - Amsterdam
4 programs
Adaptive Servo VentilationN/A1 trial
Alice PDx with only written instructionsN/A1 trial
Analysis with AED and manual PSG scoringN/A1 trial
Continuous Positive Airway PressurePHASE_31 trial
Active Trials
NCT01128816Terminated732Est. Mar 2022
NCT00841906Completed32Est. Sep 2009
NCT00836758Completed115Est. Aug 2009
+1 more trials
LivaNova
LivaNovaUK - London
2 programs
The remedē® System for the Treatment of Central Sleep Apnea in Daily PracticeN/A1 trial
pacemaker diagnostic algorithmN/A1 trial
Active Trials
NCT02577445Terminated31Est. Oct 2016
NCT02751021Completed66Est. Jun 2019
Zoll
ZollCA - San Jose
1 program
Dual Channel StimulationN/A1 trial
Active Trials
NCT06556693Recruiting40Est. Dec 2034
Rhine Pharma
Rhine PharmaGermany - Heidelberg
1 program
Echocardiographic and sleep apnea testN/A1 trial
Active Trials
NCT02296710Completed132Est. Mar 2017
Masimo
MasimoIRVINE, CA
1 program
RAM sensorN/A1 trial
Active Trials
NCT03120897Terminated78Est. Oct 2018
Medtronic
MedtronicNJ - Phillipsburg
1 program
Tri Staple Technology staplerN/A1 trial
Active Trials
NCT01026103Completed28Est. Mar 2011
Takeda
TakedaTOKYO, Japan
1 program
DanavorextonPHASE_21 trial
Active Trials
NCT05814016Terminated41Est. Sep 2024
Eisai
EisaiChina - Liaoning
1 program
ZonisamidePHASE_21 trial
Active Trials
NCT01765608Completed50Est. Jun 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ResMedEszopiclone
PhilipsContinuous Positive Airway Pressure
ApnimedSivopixant
TakedaDanavorexton
EisaiZonisamide
MSDMontelukast
VIVUSVI-0521
MSDSuvorexant
ZollDual Channel Stimulation
Invicta MedicalTarget stimulation
Invicta MedicalTarget Stimulation
Invicta MedicalHypoglossal nerve and/or Ansa Cervicalis stimulation
Invicta MedicalHypoglossal nerve stimulation
Invicta MedicalHypoglossal nerve stimulation
ResMedAirSense 10 AutoSet for Her

Showing 15 of 28 trials with date data

Clinical Trials (28)

Total enrollment: 5,718 patients across 28 trials

NCT07332442ResMedEszopiclone

Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea

Start: Feb 2026Est. completion: Jun 2030250 patients
Phase 3Not Yet Recruiting
NCT00738179PhilipsContinuous Positive Airway Pressure

Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease

Start: Sep 2008Est. completion: Dec 20152,500 patients
Phase 3Unknown
NCT06776432ApnimedSivopixant

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

Start: Apr 2025Est. completion: Dec 202560 patients
Phase 2Recruiting
NCT05814016TakedaDanavorexton

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Start: May 2023Est. completion: Sep 202441 patients
Phase 2Terminated
NCT01765608EisaiZonisamide

Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients

Start: Mar 2010Est. completion: Jun 201350 patients
Phase 2Completed
NCT00599534MSDMontelukast

Controlled Trial on Effect of Montelukast Treatment in Children With Obstructive Sleep Apnea Syndrome

Start: Dec 2007Est. completion: Dec 20090
Phase 2Withdrawn
NCT00745251VIVUSVI-0521

A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

Start: Aug 2008Est. completion: Dec 200945 patients
Phase 1/2Completed
NCT01300455MSDSuvorexant

Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)

Start: Mar 2011Est. completion: Aug 201126 patients
Phase 1Completed
NCT06556693ZollDual Channel Stimulation

Janus II Feasibility

Start: Aug 2025Est. completion: Dec 203440 patients
N/ARecruiting
NCT06627127Invicta MedicalTarget stimulation

A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea

Start: Nov 2023Est. completion: Nov 202435 patients
N/ARecruiting
NCT06635265Invicta MedicalTarget Stimulation

A Study to Determine the Flow Changes And/or AHI Reduction When Stimulating Two Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea in Adult Subjects

Start: Apr 2023Est. completion: Jul 20243 patients
N/ACompleted
NCT06415981Invicta MedicalHypoglossal nerve and/or Ansa Cervicalis stimulation

Proof-of-Concept Study to Determine the Flow Changes When Stimulating Two Neural Targets for the Treatment of Obstructive Sleep Apnea

Start: Dec 2022Est. completion: Jul 20247 patients
N/AActive Not Recruiting
NCT06283017Invicta MedicalHypoglossal nerve stimulation

Evaluation of the Effects of Hypoglossal Nerve Stimulation in Humans With Obstructive Sleep Apnea

Start: Jun 2022Est. completion: Mar 202414 patients
N/AUnknown
NCT06283030Invicta MedicalHypoglossal nerve stimulation

Evaluation of Hypoglossal Nerve Stimulation in Humans With Obstructive Sleep Apnea

Start: Dec 2021Est. completion: Sep 202314 patients
N/ACompleted
NCT03043703ResMedAirSense 10 AutoSet for Her

AirSense 10 AHI Validation Study

Start: Apr 2019Est. completion: Jun 20200
N/AWithdrawn
NCT03835702ResMedSAM Clinic Intervention

SAMPAP Trial -Impact of a Novel Sleep Apnea Management Group Intervention on Positive Airway Pressure Adherence

Start: Apr 2019Est. completion: Jun 202556 patients
N/ACompleted
NCT02751021LivaNovapacemaker diagnostic algorithm

Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction

Start: Jun 2016Est. completion: Jun 201966 patients
N/ACompleted
NCT03120897MasimoRAM sensor

Rainbow Acoustic Monitoring (RAM) Clinical Engineering Data Collection

Start: Jun 2016Est. completion: Oct 201878 patients
N/ATerminated
NCT02577445LivaNovaThe remedē® System for the Treatment of Central Sleep Apnea in Daily Practice

The remedē® System for the Treatment of Central Sleep Apnea in Daily Practice

Start: Feb 2016Est. completion: Oct 201631 patients
N/ATerminated
NCT02296710Rhine PharmaEchocardiographic and sleep apnea test

Echocardiographic Parameter and Sleep Apnea Changes After Mitral Valve Surgery

Start: Aug 2014Est. completion: Mar 2017132 patients
N/ACompleted
NCT01830036ResMedRehaSleep Register - Prevalence of Sleep Apnea in Cardiac Rehabilitation

RehaSleep Register - Prevalence of Sleep Apnea in Cardiac Rehabilitation

Start: Jun 2011Est. completion: Apr 20171,300 patients
N/AUnknown
NCT01128816PhilipsAdaptive Servo Ventilation

Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure

Start: May 2010Est. completion: Mar 2022732 patients
N/ATerminated
NCT01026103MedtronicTri Staple Technology stapler

Tri Staple Technology Stapler Used in Gastric Bypass

Start: Jan 2010Est. completion: Mar 201128 patients
N/ACompleted
NCT00263757ResMedAdaptive Servo-Ventilation

Atrial Fibrillation Recurrence in Sleep Apnea

Start: Oct 2009Est. completion: May 201225 patients
N/ACompleted
NCT00906958ResMedNexus Flow Generator

Modified AutoSet Device vs Existing AutoSet Device, the Assessment of Efficacy and Subjective Comfort of the Treatment.

Start: May 2009Est. completion: Jun 200920 patients
N/ACompleted
NCT00836758PhilipsAnalysis with AED and manual PSG scoring

Comparison of Breathing Event Detection by a Continuous Positive Airway Pressure Device to Clinical Polysomnography

Start: Feb 2009Est. completion: Aug 2009115 patients
N/ACompleted
NCT00841906PhilipsAlice PDx with only written instructions

Alice PDx User/Validation Extended Trial

Start: Sep 2008Est. completion: Sep 200932 patients
N/ACompleted
NCT01196117ResMed14 days of placebo therapy

Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea

Start: Nov 2004Est. completion: Dec 201118 patients
N/ACompleted

Related Jobs

Senior Director, Sales Training & Effectiveness

Mineralys TherapeuticsMineralys Therapeutics
Remote
3d ago
$215K - $250K/yr

Specialist, Quality Assurance

Axsome TherapeuticsAxsome Therapeutics
New York, NY
4d ago
$80K - $93K/yr

Digital Center of Excellence Project Manager

Mineralys TherapeuticsMineralys Therapeutics
Remote
5d ago
$140K - $157K/yr

Regional Business Director, Symbravo (Southwest Region)

Axsome TherapeuticsAxsome Therapeutics
Salt Lake City, UT
5d ago
$165K - $205K/yr

Regional Business Director, Symbravo (Southeast Region)

Axsome TherapeuticsAxsome Therapeutics
Atlanta, GA
5d ago
$165K - $205K/yr

National Business Director, Symbravo (West)

Axsome TherapeuticsAxsome Therapeutics
Denver, CO
5d ago
$240K - $275K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 5,718 patients
17 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.